Accuray Incorporated recently revealed the acquisition of the Providence Swedish Radiosurgery Center in Seattle, WA, of the latest generation CyberKnife S7 System. This advanced acquisition signifies a significant leap forward in the hospital’s capabilities, particularly in its cancer treatment provisions. The robotic nature of the device promises precision and accuracy, positioning it as a prime candidate for treating neurologic issues. Notably, this groundbreaking delivery device has the potential to execute extremely precise radiation treatments in only 1-5 sessions.
Price Performance
Over the past six months, ARAY’s shares witnessed a 35.4% decline, in stark contrast to the 3.1% decrease in the industry. During the same period, the S&P 500 exhibited a 6.8% incline.
Image Source: Zacks Investment Research
Latest Developments
The CyberKnife S7 System, a non-invasive radiation therapy tool, is designed to offer doctors the operational efficiency and speed they need without sacrificing the precision and accuracy required for stereotactic body radiation therapy and stereotactic radiosurgery. Moreover, the robotic architecture of the device will enable precision and accuracy, making it an excellent choice for the treatment of neurologic disorders.
Incorporating artificial intelligence, the system can track and automatically adjust for tumor or patient movement during treatment, allowing for the delivery of radiation doses to the target in just 15 minutes and with sub-millimeter precision. With a promising outlook, Accuray’s CyberKnife System is poised to capitalize on its potential in the precision Treatment Planning System and radiosurgery market.
Market Prospects and Milestones
A report by Predence Research forecasts an 8% growth in the global radiation therapy market, which reached a value of $7.3 billion in 2022 and is anticipated to surpass $14.9 billion by 2032. Advanced technologies in radiation therapy play a pivotal role in driving the market’s growth, facilitated by enhanced efficiency, efficacy, and escalating market demands from an expanding customer base.
Accuray has been making waves in the industry with its VitalHold package launch in Japan and the CNNC-Accuray joint venture Tomo C radiation therapy system approval from the Chinese National Medical Products Administration. These strategic milestones have notably advanced breast cancer treatment and expanded the options available for cancer patients undergoing radiotherapy, cementing Accuray’s position as an industry leader.
Zacks Rank & Stocks to Watch
At present, ARAY maintains a Zacks Rank #3 (Hold).
Some noteworthy stocks to consider in the broader medical domain include Universal Health Services, Integer Holdings Corporation, and Acadia Healthcare. Universal Health Services, currently holding a Zacks Rank of #2 (Buy), is estimated to achieve a growth rate of 4.4% in 2024. Meanwhile, Integer Holdings, also carrying a Zacks Rank of 2, boasts an estimated long-term growth rate of 15.8%, outperforming the industry with a 43.5% surge in the past year.
Acadia Healthcare, with a Zacks Rank of 2, and an estimated long-term growth rate of 10.4%, has witnessed an 11.7% increase in shares over the past six months, further solidifying its potential. With these exciting prospects on the horizon, the medical space continues to be a hotspot for investors seeking promising opportunities in the rapidly evolving industry.
Wrapping Up
Accuray’s game-changing CyberKnife S7 System is set to revolutionize the landscape of modern radiation treatment, promising unparalleled precision and efficacy. With the global radiation therapy market poised to experience exponential growth, industry leaders such as Accuray are well-positioned to capitalize on this momentum and drive innovation in cancer treatment technology. As Accuray continues to pave the way for advancements in precision treatment planning and radiosurgery, investors are keeping a keen eye on the company’s next milestones.
